At the annual American Urological Association (AUA) meeting this week in Washington DC, Dr Matthew Smith from Mass General Hospital presented updated data from the phase III 147 trial comparing denosumab to placebo in managing skeletal related events (SREs) and bone metastases-free survival. Skeletal complications are a major cause of prostate cancer morbidity.
The results were somewhat controversial, however, because while surrogate measures such as delaying time to SREs clearly show a benefit in favour of denosumab, no difference in overall survival was seen over placebo.
To find out whether these measures are clinically meaningful or not, I chatted with Dr Neal Shore, a urologist who is the Medical Director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina as part of the ongoing Making a Difference series of interviews.
To hear what Dr Shore had to say about the results, click on one of the links below to listen to the short podcast (one of the links works on flash so may not be visible to all readers):
[wpaudio url=”http://126.96.36.199/~icarusc2/pharmastrategyblog/wp-content/uploads/2011/05/AUA-2011-Sally-Church-Interview-with-Dr-Neil-Shore-about-Denosumab1.mp3″ dl=”http://download-host.com/mp3_download_url”]